Sign In
Buy DCPH
$25.59
+0 (+0%)
At Close: Sep 09, 2024
3 Biotech Stocks Under $5 With Massive Upside Potential
01:45pm, Thursday, 21'st May 2020
Is it May 2020 or March 2009? As Wall Street observers traverse the confused economic environment, flashbacks of the Great Recession are coming to mind.
MP welcomes Durham Council's cautious stance on schools reopening
03:40pm, Wednesday, 20'th May 2020
Easington MP Grahame Morris welcomed news that parents would not be fined for deciding to keep children at home
Exertis MD on full-year results: 'The only place we went backwards is the UK'
08:00am, Wednesday, 20'th May 2020
Distie's group managing director talk to CRN about the challenges impacting its growth in the UK market and his plan to overcome them
Deciphera's GIST Approval, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:CCXI)
08:21am, Tuesday, 19'th May 2020
Deciphera's Qinlock received FDA approval for GIST cancers. Chemocentryx reports below par kidney data. Moderna is up on positive COVID-19 data news.
Pipeline Review for Cathepsin B - H1 2020 - ResearchAndMarkets.com
12:00am, Tuesday, 19'th May 2020
The
Deciphera Pharmaceuticals Just Surged Higher On A Rapid Approval
08:16pm, Monday, 18'th May 2020
Deciphera stock popped Monday after the biotech gained FDA approval for a stomach cancer treatment. The drug, known by brand name Qinlock, treats gastrointestinal stromal tumors.
Deciphera (DCPH) Secures Early FDA Nod for GIST Drug Qinlock
04:22pm, Monday, 18'th May 2020
The FDA lends a speedy nod to Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumors. The approval comes three months ahead of schedule.
Spectrum auction likely to be held before October without 5G radiowaves
01:51pm, Monday, 18'th May 2020
"Four bidders have qualified in the technical round. They include 2 firms that have experience of spectrum auction. In case an experienced firm is selected, then the auction can begin after two months
Nomura Sticks to Their Hold Rating for Deciphera Pharmaceuticals
10:15am, Monday, 18'th May 2020
Nomura analyst Christopher Marai maintained a Hold rating on Deciphera Pharmaceuticals (NASDAQ:DCPH) on Friday, setting a price target of $60, which is approximately 15.96% above the present share pri
Xconomy: Deciphera Pharmaceuticals Wins Early FDA Nod for GI Cancer Treatment
11:48pm, Friday, 15'th May 2020
Some patients with a deadly type of tumor that forms in the gastrointestinal tract don’t respond to existing targeted therapies. On Friday the FDA
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the U.S. Food and Drug Administration (FDA) has approved QINLOCK™ (ripretinib) for the treatment of adult patients with advanced gastroi
Liverpool news and transfers - Timo Werner race hots up
09:44pm, Tuesday, 12'th May 2020
Latest Liverpool news and transfer rumours
Everton news and transfers - Moise Kean advised on future
09:44pm, Tuesday, 12'th May 2020
Latest Everton news and transfer rumours
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Analysts Just Trimmed Their Revenue Forecasts By 14%
10:53am, Tuesday, 12'th May 2020
The analysts covering Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) delivered a dose of negativity to shareholders...
